{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:14:32Z","timestamp":1766182472988,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejphar.2025.177293","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T17:58:01Z","timestamp":1737655081000},"page":"177293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Thrombolytic efficacy and safety of recombinant scu-PA in a rabbit retinal vein occlusion model"],"prefix":"10.1016","volume":"991","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2451-3946","authenticated-orcid":false,"given":"Dawei","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177293_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/21655979.2016.1229718","article-title":"The evolution of recombinant thrombolytics: Current status and future directions","volume":"8","author":"Adivitiya","year":"2017","journal-title":"Bioengineered"},{"key":"10.1016\/j.ejphar.2025.177293_bib2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IAE.0b013e318140580c","article-title":"Intravitreal and subretinal injection of tissue plasminogen activator (tPA) in the treatment of experimentally created retinal vein occlusion in rabbits","volume":"28","author":"Ameri","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ejphar.2025.177293_bib3","first-page":"93","article-title":"Bio-transformation and pharmacokinetics of single chain urokinase-type plasminogen activator in rabbits and rhesus monkeys","volume":"35","author":"Dou","year":"2000","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.ejphar.2025.177293_bib4","first-page":"471","article-title":"Thrombolytic therapy for central retinal vein occlusion: results of a pilot study","volume":"94","author":"Elman","year":"1996","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.ejphar.2025.177293_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3892\/etm.2022.11739","article-title":"Safety and efficacy of intracoronary recombinant human prourokinase administration in patients with acute myocardial infarction and ST-segment elevation: a meta-analysis of randomized controlled trials","volume":"25","author":"Fan","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejphar.2025.177293_bib6","doi-asserted-by":"crossref","first-page":"P288","DOI":"10.1016\/j.ophtha.2019.09.029","article-title":"Retinal vein occlusions Preferred Practice Pattern(R)","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejphar.2025.177293_bib7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.asjsur.2022.09.115","article-title":"Efficacy of half-dose recombinant human prourokinase thrombolysis combined with early PCI in 48 patients with ST-segment-elevation myocardial infarction (STEMI)","volume":"46","author":"Gao","year":"2023","journal-title":"Asian J. Surg."},{"key":"10.1016\/j.ejphar.2025.177293_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00006982-200507001-00008","article-title":"Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases","volume":"25","author":"Green","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.ejphar.2025.177293_bib9","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1172\/JCI113815","article-title":"Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158)","volume":"82","author":"Gurewich","year":"1988","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2025.177293_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejphar.2017.11.026","article-title":"Effect of human recombinant prourokinase(rhpro-UK) on thromboembolic stroke in rats","volume":"818","author":"Hao","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177293_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/09286586.2020.1792937","article-title":"Real-world visual and neovascularisation Outcomes from anti-VEGF in central retinal vein occlusion","volume":"28","author":"Hogg","year":"2021","journal-title":"Ophthalmic Epidemiol."},{"key":"10.1016\/j.ejphar.2025.177293_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1442-9071.1993.tb00959.x","article-title":"An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions","volume":"21","author":"Jefferies","year":"1993","journal-title":"Aust. N. Z. J. Ophthalmol."},{"key":"10.1016\/j.ejphar.2025.177293_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/ICU.0000000000001045","article-title":"Retinal arterial and vein occlusion: is surgery ever indicated?","volume":"35","author":"Kadonosono","year":"2024","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.ejphar.2025.177293_bib14","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1167\/iovs.17-22788","article-title":"Animal models of retinal vein occlusion","volume":"58","author":"Khayat","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejphar.2025.177293_bib15","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1074\/jbc.M110.204537","article-title":"Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1","volume":"286","author":"Lin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177293_bib16","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1021\/bi00142a021","article-title":"Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK","volume":"31","author":"Liu","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2025.177293_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10143080","article-title":"Platelet and Thrombophilia-Related risk factors of retinal vein occlusion","volume":"10","author":"Marcinkowska","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2025.177293_bib18","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1097\/HS9.0000000000000570","article-title":"The fibrinolytic system: Mysteries and Opportunities","volume":"5","author":"Medcalf","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.ejphar.2025.177293_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9875741","article-title":"Differentiation between good and low-Responders to intravitreal ranibizumab for macular edema secondary to retinal vein occlusion","author":"Menke","year":"2016","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ejphar.2025.177293_bib20","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/jth.14950","article-title":"Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets","volume":"18","author":"Ni","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejphar.2025.177293_bib21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0304-4165(77)90321-X","article-title":"Plasminogen activator from human embryonic kidney cell cultures. Evidence for a proactivator","volume":"496","author":"Nolan","year":"1977","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2025.177293_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00006982-200603000-00009","article-title":"Radial optic neurotomy with adjunctive intraocular triamcinolone for central retinal vein occlusion: 63 consecutive cases","volume":"26","author":"Opremcak","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ejphar.2025.177293_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejphar.2025.177293_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000502041","article-title":"Guidelines for the management of retinal vein occlusion by the European Society of retina Specialists (EURETINA)","volume":"242","author":"Schmidt-Erfurth","year":"2019","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ejphar.2025.177293_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-023-01051-2","article-title":"Thrombolysis with recombinant human prourokinase 4.5-6 h after acute ischemic stroke: a phase IIa, randomized, and open-label Multicenter clinical trial","volume":"38","author":"Song","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2025.177293_bib26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s12975-022-01012-9","article-title":"Efficacy and safety of recombinant human prourokinase in acute ischemic stroke: a phase IIa randomized clinical trial","volume":"13","author":"Song","year":"2022","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.ejphar.2025.177293_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.25415","article-title":"Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial","volume":"6","author":"Song","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejphar.2025.177293_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/svn-2023-002673","article-title":"Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial","author":"Xiong","year":"2024","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.ejphar.2025.177293_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00380-017-1097-x","article-title":"Safety and efficacy of prourokinase injection in patients with ST-elevation myocardial infarction: phase IV clinical trials of the prourokinase phase study","volume":"33","author":"Zhao","year":"2018","journal-title":"Heart Ves."},{"key":"10.1016\/j.ejphar.2025.177293_bib30","article-title":"Exogenous urokinase Inhibits Proteasomal degradation of its Cognate urokinase plasminogen activator Receptor","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T09:57:46Z","timestamp":1740391066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"alternative-id":["S0014299925000469"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177293","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombolytic efficacy and safety of recombinant scu-PA in a rabbit retinal vein occlusion model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177293"}}